GSK may not have been surprised its anti-TIM-3 drug couldn’t secure a phase 3 win based on how its pharma peers have struggled. (iStock / Getty Images Plus) GSK’s cobolimab has become the latest ...

Two Sarepta Therapeutics drugs for treating different genetic subsets of patients with Duchenne muscular dystrophy failed the confirmatory study required of their accelerated FDA approvals. Sarepta ...

– PDE9 inhibitor, CRD-740, demonstrated favorable safety profile and achieved statistical significance for the trial’s primary endpoint, median increase in plasma cyclic guanosine monophosphate (cGMP) ...

BioCardia said that CardiAMP was associated with “trends” toward reduced ventricular tachyarrhythmias and enhanced heart function as measured by left ventricular ejection fraction. (Natalija ...

Bayer’s Kerendia, already FDA approved in one cardiometabolic indication, now has data from a pivotal test that support expanding the drug’s label to heart failure. In preliminary results reported ...

Oliguric renal failure is a phase of acute renal failure (ARF), also known as acute kidney injury (AKI), in which a person’s urine output is very low. ARF is a sudden decline in kidney functioning.

BOSTON--(BUSINESS WIRE)--Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company developing next-generation therapeutics for the treatment of ...

Patients with acute heart failure are frequently or systematically hospitalized, often because the risk of adverse events is uncertain and the options for rapid follow-up are inadequate. Whether the ...